MAPT and Alzheimer disease: Conversion to AD in MCI categories based on their core CSF biomarkers (Aβ42, t-Tau and p-Tau) showed that subjects in the HL group were more prone to progress to AD (75.0%), than all other biomarker groups: SNAP, 55.6%; IAP, 43.8%; LL, 10.0% (p < 0.001) (Table 4).